Welcome to our dedicated page for SpyGlass Pharma SEC filings (Ticker: SGP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SpyGlass Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SpyGlass Pharma's regulatory disclosures and financial reporting.
SpyGlass Pharma completed its initial public offering, selling 10,781,250 shares of common stock, including 1,406,250 from the full exercise of the underwriters’ option, at $16.00 per share for aggregate gross proceeds of $172.5 million. All shares were offered by the company, and its stock now trades on the Nasdaq Global Select Market under the symbol SGP.
The company appointed industry executive Habib Dable as a Class I director and compensation committee member, granted him an option to purchase 27,400 shares vesting monthly over 36 months, and outlined ongoing annual option grants of 13,700 shares. In connection with the IPO’s completion, SpyGlass adopted an amended and restated certificate of incorporation and bylaws, which define key governance and capital structure terms.
SpyGlass Pharma, Inc. is launching its initial public offering of 9,375,000 shares of common stock at $16.00 per share, all sold by the company. The IPO is expected to generate approximately $139.5 million in gross proceeds, or about $135.2 million net after underwriting fees and expenses.
The underwriters have a 30‑day option to buy up to 1,406,250 additional shares, which would raise total net proceeds to about $156.1 million. SpyGlass is a late‑stage biopharmaceutical company developing long‑acting drug‑delivery implants for glaucoma and ocular hypertension, led by its bimatoprost Drug Pad‑IOL System now in Phase 3 trials.
SpyGlass Pharma 10% owner Vensana Capital I, L.P. reports indirect holdings of multiple preferred stock series that will convert into common shares before the company’s initial public offering.
The filing lists indirect holdings by Vensana Capital I, L.P. of Series B Preferred Stock convertible into 1,690,230 shares of common stock, Series C-1 Preferred Stock convertible into 548,067 shares, Series C-2 Preferred Stock convertible into 548,067 shares, and Series D Preferred Stock convertible into 359,255 shares. All preferred shares automatically convert to common stock on a one-for-one basis prior to the IPO. The interests are attributed to Vensana Capital I, L.P., with its general partner and two managing directors disclaiming beneficial ownership except for their respective pecuniary interests.
SpyGlass Pharma, Inc. received an initial ownership report on Form 3 from Baskett Forest, identified as a more-than-10% owner. The filing lists indirect holdings of several series of preferred stock through New Enterprise Associates funds, including 1,619,240 shares of Series B and 954,990 shares of Series A preferred.
All reported preferred shares automatically convert into common stock on a one-for-one basis before the closing of SpyGlass Pharma’s initial public offering, giving investors a clearer picture of pre-IPO ownership held via NEA 16 and NEA 17 structures.
SpyGlass Pharma’s 10% owner associated with NEA 17 has filed an initial ownership report detailing large preferred stock positions that are convertible into common shares. The filing lists indirect holdings of Series B, C-1, C-2 and D preferred stock, which will automatically convert to common stock on a one-for-one basis before the closing of SpyGlass Pharma’s initial public offering. These securities are held directly by New Enterprise Associates 17, L.P., with the reporting person acting through related general partner entities and disclaiming beneficial ownership of portions in which there is no pecuniary interest.
SpyGlass Pharma’s 10% owner Carmen Chang filed an initial ownership report detailing indirect stakes in multiple series of the company’s preferred stock. The preferred shares are held through New Enterprise Associates funds, including NEA 16 and NEA 17, via their general partner entities. All preferred shares will automatically convert on a one-for-one basis into SpyGlass Pharma common stock before the closing of its initial public offering. Chang disclaims beneficial ownership of portions of the NEA 16 and NEA 17 holdings in which she has no pecuniary interest.
SpyGlass Pharma, Inc. insider Florence Anthony A. Jr., a 10% owner, filed a Form 3 reporting indirect holdings of multiple preferred stock series. These include Series B preferred stock convertible into 1,619,240 shares of common stock and Series A preferred stock convertible into 954,990 common shares.
All reported preferred shares automatically convert into common stock on a one-for-one basis before the closing of SpyGlass Pharma’s initial public offering. The securities are directly owned by New Enterprise Associates funds, while Anthony serves in managing roles at their general partners and disclaims beneficial ownership where he has no pecuniary interest.
SpyGlass Pharma, Inc. director and 10% owner Ali Behbahani filed an initial Form 3 reporting indirect holdings of several series of preferred stock. These include 1,619,240 shares of Series B Preferred Stock and 954,990 shares of Series A Preferred Stock through New Enterprise Associates funds. All preferred shares will automatically convert on a one-for-one basis into common stock before the closing of SpyGlass Pharma’s initial public offering. Behbahani reports these interests through NEA 16 and NEA 17 structures and disclaims beneficial ownership of portions in which he has no pecuniary interest.
SpyGlass Pharma, Inc. 10% owner Paul Edward Walker filed an initial ownership report showing indirect holdings of multiple series of preferred stock as of February 5, 2026. These include Series A, B, C-1, C-2 and D preferred shares, each convertible into common stock on a one-for-one basis before the company’s initial public offering.
The preferred shares reported are held through New Enterprise Associates funds NEA 16 and NEA 17, via their general partner entities. Walker is a manager of the relevant general partners and disclaims beneficial ownership of any portions in which he has no pecuniary interest.
SpyGlass Pharma 10% owner Scott D. Sandell filed an initial Form 3 reporting indirect holdings of multiple preferred stock series that are convertible into common shares. All preferred stock will automatically convert on a one-for-one basis into common stock before the closing of SpyGlass Pharma’s initial public offering. The securities are directly held by New Enterprise Associates funds NEA 17 and NEA 16, with Sandell serving as a manager of their general partner entities and disclaiming beneficial ownership of portions in which he has no pecuniary interest.